세계의 리포솜 독소루비신 시장 보고서(2025년)

Liposomal Doxorubicin Global Market Report 2025

US $ 4,490 ￦ 6,371,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,209,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,048,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

리포솜 독소루비신 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 6.8%의 성장률로 17억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장에는 암 치료 옵션에 대한 인식 증가, 임상시험 증가, 병용요법 채택 증가, 의료 지출 증가, 표적 치료 선호도 증가 등이 영향을 미칠 것으로 보입니다. 예측 기간의 주요 동향으로는 신약 개발을 촉진하기 위한 인공지능(AI)과 머신러닝 알고리즘의 통합, 3D 프린팅 기술 활용, 자기 표적화 방법, 종양 침투 펩타이드 및 초음파를 통한 약물전달과 같은 혁신적인 전략, 약물전달 기술의 발전 등을 들 수 있습니다.

암의 유병률 증가는 향후 몇 년 동안 리포솜 독소루비신 시장의 성장을 촉진할 것으로 예상됩니다. 암은 거의 모든 장기와 조직에서 발생할 수 있는 질병군으로, 정상 경계를 넘어 다른 장기나 주변 신체 부위로 전이되는 비정상적인 세포 증식으로 인해 발생합니다. 암 환자의 증가는 고령화, 생활습관의 변화, 환경 노출, 진단 방법의 발전 등의 요인에 기인합니다. 리포솜 독소루비신은 암 치료에서 종양으로의 약물전달을 개선하고, 독성을 최소화하며, 치료 효과를 높이기 위해 사용됩니다. 예를 들어, 2024년 1월 미국 비영리 단체인 미국 암 협회는 2023년 195만 8,310명에서 2024년 200만 1,140명으로 암 환자가 증가할 것이라고 보고했으며, 이는 2.19%의 성장률을 반영하는 것입니다. 결과적으로 암 유병률의 증가가 리포솜 독소루비신 시장의 성장을 촉진하고 있습니다.

리포솜 독소루비신 시장의 주요 기업들은 독소루비신의 약동학 및 분포를 강화하고 환자 결과를 개선하기 위해 PEG화 리포솜과 같은 약물전달 시스템의 발전에 주력하고 있습니다. 이러한 기술 혁신을 통해 부작용을 줄이면서 암세포에 더 효과적으로 약물을 전달할 수 있습니다. 예를 들어, 2022년 5월 어코드 헬스케어는 널리 사용되는 암 치료제 독소루비신의 제네릭 대체품으로 PEG화 리포솜 2mg/ml 농축 수액 분산액인 졸스케틸을 출시했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 리포솜 독소루비신 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 리포솜 독소루비신 시장 : 성장률 분석
• 세계의 리포솜 독소루비신 시장 실적 : 규모와 성장, 2019-2024
• 세계의 리포솜 독소루비신 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 리포솜 독소루비신 전체 시장(TAM)

제6장 시장 세분화

• 세계의 리포솜 독소루비신 시장 : 제품별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 드키실 또는 카에리크스
• 리포족스
• 미오셋트
• 기타 제품
• 세계의 리포솜 독소루비신 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 비경구
• 기타 투여 경로
• 세계의 리포솜 독소루비신 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 백혈병
• 골육종
• 유방암
• 자궁내막암
• 신장암
• 다발성 골수종
• 카포시육종
• 기타 용도
• 세계의 리포솜 독소루비신 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 홈케어
• 기타 최종사용자
• 세계의 리포솜 독소루비신 시장, 드키실 또는 Caelyx 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 다른 용량 강도
• 브랜드 버전
• 제네릭 버전
• 세계의 리포솜 독소루비신 시장 Lipodox 하위 세분화(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 다른 용량 강도
• 브랜드 버전
• 제네릭 버전
• 세계의 리포솜 독소루비신 시장, 미오셋트 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 다른 용량 강도
• 브랜드 버전
• 제네릭 버전
• 세계의 리포솜 독소루비신 시장, 기타 제품 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 새로운 리포솜 제제
• 지역 브랜드 베리에이션
• 병용요법

제7장 지역별·국가별 분석

• 세계의 리포솜 독소루비신 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 리포솜 독소루비신 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 리포솜 독소루비신 시장 : 경쟁 구도
• 리포솜 독소루비신 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd
• Baxter International Inc.
• Astellas Pharma
• Sun Pharmaceutical Industries Ltd
• Jazz Pharmaceuticals
• Cipla Inc.
• Endo Pharmaceuticals
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Zydus Cadila
• Accord Healthcare Limited
• Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd
• TTY Biopharm Company Limited

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 리포솜 독소루비신 시장 2029 : 새로운 기회를 제공하는 국가
• 리포솜 독소루비신 시장 2029 : 새로운 기회를 제공하는 부문
• 리포솜 독소루비신 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Liposomal doxorubicin is a form of the chemotherapy drug doxorubicin enclosed within lipid bilayers, forming tiny vesicles known as liposomes. This encapsulation modifies how the drug moves through the body, leading to longer circulation in the bloodstream and increased accumulation at tumor sites due to improved permeability and retention effects. Liposomal doxorubicin is employed in treating different cancers such as ovarian cancer, breast cancer, and Kaposi's sarcoma, potentially reducing the risk of heart-related side effects compared to traditional doxorubicin formulations.

The primary types of liposomal doxorubicin include Doxil or Caelyx, Lipodox, Myocet, and others. Doxil, also marketed as Caelyx, is a specific brand of liposomal doxorubicin used in chemotherapy for various cancer types. It is administered via injection and is applied in treating leukemia, bone sarcoma, breast cancer, endometrial cancer, kidney cancer, multiple myeloma, Kaposi sarcoma, among others. It is utilized by various end-users including hospitals, home care settings, and others.

The liposomal doxorubicin market research report is one of a series of new reports from The Business Research Company that provides liposomal doxorubicin market statistics, including liposomal doxorubicin industry global market size, regional shares, competitors with a liposomal doxorubicin market share, detailed liposomal doxorubicin market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal doxorubicin industry. This liposomal doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liposomal doxorubicin market size has grown strongly in recent years. It will grow from $1.23 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to improved liposome formulations, favorable reimbursement policies for cancer treatments, growing awareness about the importance of cancer screening programs, enhanced healthcare infrastructure, and increasing patient preference for minimally invasive cancer treatments.

The liposomal doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.72 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising awareness about cancer treatment options, increasing clinical trials, increasing adoption of combination therapies, rising healthcare expenditure, and growing preference for targeted therapies. Major trends in the forecast period include the integration of artificial intelligence (AI) and machine learning algorithms to facilitate drug discovery, utilizing 3D printing technologies, magnetic targeting methods, innovative strategies such as tumor-penetrating peptides or ultrasound-mediated drug delivery, and advancements in drug delivery technology.

The increasing prevalence of cancer is expected to drive the growth of the liposomal doxorubicin market in the coming years. Cancer is a group of diseases that can occur in almost any organ or tissue, caused by abnormal cell growth that spreads beyond its normal boundaries, invading other organs or neighboring body parts. The rise in cancer cases can be attributed to factors such as an aging population, lifestyle changes, environmental exposures, and advancements in diagnostic methods. Liposomal doxorubicin is used in cancer therapy to improve drug delivery to tumors, minimize toxicity, and enhance treatment outcomes. For example, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization, reported an increase in cancer cases to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth rate of 2.19%. As a result, the growing prevalence of cancer is fueling the growth of the liposomal doxorubicin market.

Key players in the liposomal doxorubicin market are concentrating on advancing drug delivery systems such as PEGylated liposomes to enhance the pharmacokinetics and distribution of doxorubicin, thereby improving patient outcomes. These innovations ensure drugs are targeted more effectively to cancer cells while reducing side effects. For instance, in May 2022, Accord Healthcare Limited introduced Zolsketil, a pegylated liposomal 2mg/ml concentrate for infusion dispersion, as a generic alternative to doxorubicin, a widely used cancer treatment.

In January 2024, CHEPLAPHARM Arzneimittel GmbH, a Germany-based pharmaceutical company, acquired the European rights to Myocet from Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition strengthens CHEPLAPHARM's oncology portfolio by adding Myocet, a non-pegylated liposomal doxorubicin formulation, in line with its strategy to incorporate well-established drugs. Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, offers the liposomal doxorubicin formulation Myocet.

Major companies operating in the liposomal doxorubicin market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd, Baxter International Inc., Astellas Pharma, Sun Pharmaceutical Industries Ltd, Jazz Pharmaceuticals, Cipla Inc., Endo Pharmaceuticals, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila, Accord Healthcare Limited, Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd, TTY Biopharm Company Limited, SRS Life Sciences

North America was the largest region in the liposomal doxorubicin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liposomal doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liposomal doxorubicin market consists of sales of Doxil and Lipodox. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liposomal Doxorubicin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liposomal doxorubicin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liposomal doxorubicin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liposomal doxorubicin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Doxil Or Caelyx; Lipodox; Myocet; Other Products
• 2) By Route Of Administration: Parenteral; Other Routes Of Administration
• 3) By Application: Leukemia; Bone Sarcoma; Breast Cancer; Endometrial Cancer; Kidney Cancer; Multiple Myeloma; Kaposi Sarcoma; Other Applications
• 4) By End-Users: Hospitals; Homecare; Other End-Users
• Subsegments:
• 1) By Doxil Or Caelyx: Different Dosage Strengths; Branded Versions; Generic Versions
• 2) By Lipodox: Different Dosage Strengths; Branded Versions; Generic Versions
• 3) By Myocet: Different Dosage Strengths; Branded Versions; Generic Versions
• 4) By Other Products: Newer Liposomal Formulations; Regional Brand Variants; Combination Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liposomal Doxorubicin Market Characteristics

3. Liposomal Doxorubicin Market Trends And Strategies

4. Liposomal Doxorubicin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Liposomal Doxorubicin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liposomal Doxorubicin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liposomal Doxorubicin Market Growth Rate Analysis
• 5.4. Global Liposomal Doxorubicin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liposomal Doxorubicin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liposomal Doxorubicin Total Addressable Market (TAM)

6. Liposomal Doxorubicin Market Segmentation

• 6.1. Global Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxil Or Caelyx
• Lipodox
• Myocet
• Other Products
• 6.2. Global Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Other Routes Of Administration
• 6.3. Global Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Bone Sarcoma
• Breast Cancer
• Endometrial Cancer
• Kidney Cancer
• Multiple Myeloma
• Kaposi Sarcoma
• Other Applications
• 6.4. Global Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Other End-Users
• 6.5. Global Liposomal Doxorubicin Market, Sub-Segmentation Of Doxil Or Caelyx, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Strengths
• Branded Versions
• Generic Versions
• 6.6. Global Liposomal Doxorubicin Market, Sub-Segmentation Of Lipodox, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Strengths
• Branded Versions
• Generic Versions
• 6.7. Global Liposomal Doxorubicin Market, Sub-Segmentation Of Myocet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Strengths
• Branded Versions
• Generic Versions
• 6.8. Global Liposomal Doxorubicin Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Newer Liposomal Formulations
• Regional Brand Variants
• Combination Therapies

7. Liposomal Doxorubicin Market Regional And Country Analysis

• 7.1. Global Liposomal Doxorubicin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liposomal Doxorubicin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liposomal Doxorubicin Market

• 8.1. Asia-Pacific Liposomal Doxorubicin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liposomal Doxorubicin Market

• 9.1. China Liposomal Doxorubicin Market Overview
• 9.2. China Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liposomal Doxorubicin Market

• 10.1. India Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liposomal Doxorubicin Market

• 11.1. Japan Liposomal Doxorubicin Market Overview
• 11.2. Japan Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liposomal Doxorubicin Market

• 12.1. Australia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liposomal Doxorubicin Market

• 13.1. Indonesia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liposomal Doxorubicin Market

• 14.1. South Korea Liposomal Doxorubicin Market Overview
• 14.2. South Korea Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liposomal Doxorubicin Market

• 15.1. Western Europe Liposomal Doxorubicin Market Overview
• 15.2. Western Europe Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liposomal Doxorubicin Market

• 16.1. UK Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liposomal Doxorubicin Market

• 17.1. Germany Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liposomal Doxorubicin Market

• 18.1. France Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liposomal Doxorubicin Market

• 19.1. Italy Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liposomal Doxorubicin Market

• 20.1. Spain Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liposomal Doxorubicin Market

• 21.1. Eastern Europe Liposomal Doxorubicin Market Overview
• 21.2. Eastern Europe Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liposomal Doxorubicin Market

• 22.1. Russia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liposomal Doxorubicin Market

• 23.1. North America Liposomal Doxorubicin Market Overview
• 23.2. North America Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liposomal Doxorubicin Market

• 24.1. USA Liposomal Doxorubicin Market Overview
• 24.2. USA Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liposomal Doxorubicin Market

• 25.1. Canada Liposomal Doxorubicin Market Overview
• 25.2. Canada Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liposomal Doxorubicin Market

• 26.1. South America Liposomal Doxorubicin Market Overview
• 26.2. South America Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liposomal Doxorubicin Market

• 27.1. Brazil Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liposomal Doxorubicin Market

• 28.1. Middle East Liposomal Doxorubicin Market Overview
• 28.2. Middle East Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liposomal Doxorubicin Market

• 29.1. Africa Liposomal Doxorubicin Market Overview
• 29.2. Africa Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liposomal Doxorubicin Market Competitive Landscape And Company Profiles

• 30.1. Liposomal Doxorubicin Market Competitive Landscape
• 30.2. Liposomal Doxorubicin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Overview, Products and Services, Strategy and Financial Analysis

31. Liposomal Doxorubicin Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. Teva Pharmaceutical Industries Ltd
• 31.4. Baxter International Inc.
• 31.5. Astellas Pharma
• 31.6. Sun Pharmaceutical Industries Ltd
• 31.7. Jazz Pharmaceuticals
• 31.8. Cipla Inc.
• 31.9. Endo Pharmaceuticals
• 31.10. Lupin Limited
• 31.11. Mallinckrodt Pharmaceuticals
• 31.12. Zydus Cadila
• 31.13. Accord Healthcare Limited
• 31.14. Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd
• 31.15. TTY Biopharm Company Limited

32. Global Liposomal Doxorubicin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liposomal Doxorubicin Market

34. Recent Developments In The Liposomal Doxorubicin Market

35. Liposomal Doxorubicin Market High Potential Countries, Segments and Strategies

• 35.1 Liposomal Doxorubicin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liposomal Doxorubicin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liposomal Doxorubicin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료